Non Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 1st Line

Adenocarcinoma Neversmoking

EGFR Exon 20 Insertions

EGFR Mutant (Not Exon 20)

Without Actionable Genomic Alterations

**LUN0112**
Phase II Carboplatin + Pemetrexed + Bevacizumab +/- Atezolizumab in Stage IV Non-Squamous NSCLC
PI: Wakelee
NI:TN

**LUN0113**
Phase III TAK-788 First-Line Tx vs Platinum-Based Chemo in NSCLC w/ EGFR Exon 20 Insertion Mutations
PI: Neal
Sponsor: Takeda

**ECOG-ACCRIN-EA5182**
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab versus Osimertinib (AZD9291) Alone as First-Line Treatment in Metastatic EGFR-Mutant NSCLC
PI: Neal
Sponsor: ECOG-ACCRIN

**LUN0125**
Phase II Sacituzumab Govitecan Combinations in First-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer Without Actionable Genomic Alterations
PI: Neal
Sponsor: Gilead Sciences, Inc.